Loading clinical trials...
Loading clinical trials...
A Multicentre Exploratory Phase II Study Describing the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Conditions
Interventions
Treatment by Regorafenib
Surveillance
Locations
16
France
Hôpital Jean Minjoz
Besançon, France
Institut Bergonié
Bordeaux, France
Centre Oscar Lambret
Lille, France
Centre Léon Bérard
Lyon, France
APHM - Hôpital Timone
Marseille, France
ICM Val d'Aurelle
Montpellier, France
Start Date
March 3, 2020
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
February 17, 2026
NCT04308330
NCT06541262
NCT03715933
NCT07479732
NCT07144254
NCT05235165
Lead Sponsor
Centre Leon Berard
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions